DA
ARQT icon

Denali Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Denali Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,200
Closed -$23K – 422
2022
Q3 		$23K Sell
1,200
-1,400
-54% -$31.7K 0.01% 275
2022
Q2 		$55K Sell
2,600
-1,100
-30% -$22.6K 0.02% 208
2022
Q1 		$71K Hold
3,700
– – 0.03% 218
2021
Q4 		$77K Buy
+3,700
New +$73.6K 0.03% 208

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Denali Advisors's ARQT Position: Q4 2022 in Review

Denali Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2022, closing a stake of 1,200 shares — an estimated $23K sold.

Denali Advisors first reported a position in ARQT in Q4 2021 and held it in 4 quarters. The position peaked at $77K in Q4 2021. 141 funds tracked by Wall St. Rank hold ARQT as of Q4 2022.

  • Denali Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Denali Advisors sold 1,200 Arcutis Biotherapeutics shares in Q4 2022, an estimated $23K.
  • Denali Advisors first reported a position in Arcutis Biotherapeutics in Q4 2021 and held it in 4 quarters.
  • Denali Advisors's Arcutis Biotherapeutics position peaked at $77K in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2022.

Based on Denali Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.